Re­gen­eron earns mid-stage win for high­er dose of Eylea, hop­ing to re­fresh its sales pitch

Re­gen­eron has made its name on the block­buster suc­cess of eye drug Eylea, but with the ag­ing drug fac­ing a raft of com­peti­tors the drug­mak­er is look­ing for ways to keep its sales pitch fresh. And re­searchers are blaz­ing a fresh trail on that front with new mid-stage da­ta out to­day.

Forty-three per­cent of wet age-re­lat­ed mac­u­lar de­gen­er­a­tion pa­tients dosed with an 8 mg dose of Eylea re­port­ed no reti­nal flu­id af­ter four weeks com­pared with 26.4% of pa­tients re­ceiv­ing a 2 mg dose of the drug, ac­cord­ing to topline da­ta from a Phase II study un­veiled Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER